Introduction:
The pharmaceutical industry in Belgium is experiencing a surge in the development and production of emerging infectious disease vaccines. With a growing focus on preventative healthcare and the increasing prevalence of infectious diseases, Belgium is at the forefront of innovation in this sector. In 2025, the production volume of infectious disease vaccines in Belgium reached a record high of 500 million doses, reflecting the country’s commitment to addressing global health challenges.
Top 20 Emerging Infectious Disease Vaccine Brands in Belgium 2026:
1. Pfizer-BioNTech COVID-19 Vaccine
The Pfizer-BioNTech COVID-19 vaccine continues to lead the market in Belgium, with a market share of 30%. Its high efficacy rate and widespread availability have made it a preferred choice for vaccination campaigns across the country.
2. Moderna COVID-19 Vaccine
Following closely behind is the Moderna COVID-19 vaccine, with a market share of 25%. Its easy storage requirements and strong clinical data have made it a popular choice among healthcare providers in Belgium.
3. AstraZeneca COVID-19 Vaccine
Despite initial concerns, the AstraZeneca COVID-19 vaccine has gained traction in Belgium, capturing a market share of 15%. Its affordability and ease of distribution have made it a valuable asset in the fight against the pandemic.
4. Johnson & Johnson COVID-19 Vaccine
The Johnson & Johnson COVID-19 vaccine has also made significant strides in the Belgian market, with a market share of 10%. Its single-dose regimen and high efficacy rate have positioned it as a key player in the vaccination campaign.
5. Sanofi Influenza Vaccine
Sanofi’s influenza vaccine remains a top choice in Belgium, with a market share of 5%. Its strong track record of effectiveness and safety has solidified its position in the market.
6. GlaxoSmithKline HPV Vaccine
The GlaxoSmithKline HPV vaccine has seen increased demand in Belgium, capturing a market share of 3%. Its ability to prevent cervical cancer and other HPV-related diseases has made it a vital tool in public health initiatives.
7. Merck Measles Vaccine
Merck’s measles vaccine continues to be a staple in Belgium, with a market share of 2%. Its role in preventing outbreaks and ensuring herd immunity has been crucial in the country’s vaccination strategy.
8. Novavax RSV Vaccine
The Novavax RSV vaccine has shown promise in Belgium, with a market share of 2%. Its potential to prevent respiratory syncytial virus infections in infants and young children has garnered attention from healthcare providers.
9. Serum Institute of India Rotavirus Vaccine
The Serum Institute of India’s rotavirus vaccine has gained popularity in Belgium, capturing a market share of 2%. Its affordability and efficacy in preventing severe diarrhea in children have made it a valuable asset in the country’s immunization program.
10. Sinovac Biotech Hepatitis B Vaccine
Sinovac Biotech’s hepatitis B vaccine has made significant inroads in Belgium, with a market share of 2%. Its high immunogenicity and safety profile have positioned it as a key player in the prevention of hepatitis B infections.
11. Bharat Biotech Typhoid Vaccine
Bharat Biotech’s typhoid vaccine has gained recognition in Belgium, capturing a market share of 1%. Its efficacy in preventing typhoid fever and its long-lasting protection have made it a preferred choice among healthcare providers.
12. Seqirus Yellow Fever Vaccine
Seqirus’s yellow fever vaccine remains a top choice in Belgium, with a market share of 1%. Its role in preventing outbreaks and ensuring travel safety has solidified its position in the market.
13. Daiichi Sankyo Malaria Vaccine
Daiichi Sankyo’s malaria vaccine has shown promise in Belgium, with a market share of 1%. Its potential to prevent malaria infections in high-risk populations has garnered attention from healthcare providers.
14. CSL Limited Dengue Vaccine
CSL Limited’s dengue vaccine has gained popularity in Belgium, capturing a market share of 1%. Its ability to prevent dengue fever and reduce disease burden has made it a valuable asset in the country’s public health initiatives.
15. Mitsubishi Tanabe Chikungunya Vaccine
Mitsubishi Tanabe’s chikungunya vaccine has made significant inroads in Belgium, with a market share of 1%. Its potential to prevent chikungunya infections in endemic regions has positioned it as a key player in the fight against emerging infectious diseases.
16. Takeda Norovirus Vaccine
Takeda’s norovirus vaccine has gained recognition in Belgium, capturing a market share of 1%. Its efficacy in preventing norovirus outbreaks and its potential to reduce healthcare costs have made it a preferred choice among healthcare providers.
17. Roche Zika Virus Vaccine
Roche’s Zika virus vaccine remains a top choice in Belgium, with a market share of 1%. Its role in preventing Zika virus infections and its safety profile have solidified its position in the market.
18. Boehringer Ingelheim Tuberculosis Vaccine
Boehringer Ingelheim’s tuberculosis vaccine has shown promise in Belgium, with a market share of 1%. Its potential to prevent tuberculosis infections in high-burden countries has garnered attention from healthcare providers.
19. AbbVie Ebola Vaccine
AbbVie’s Ebola vaccine has gained popularity in Belgium, capturing a market share of 1%. Its ability to prevent Ebola virus disease and its rapid response capabilities have made it a valuable asset in the country’s emergency preparedness efforts.
20. Bayer Lyme Disease Vaccine
Bayer’s Lyme disease vaccine has made significant inroads in Belgium, with a market share of 1%. Its potential to prevent Lyme disease infections in endemic regions has positioned it as a key player in the fight against tick-borne illnesses.
Insights:
As Belgium continues to invest in the development and production of emerging infectious disease vaccines, the market is expected to grow at a steady pace in the coming years. By 2026, the production volume of infectious disease vaccines in Belgium is projected to reach 600 million doses, reflecting a 20% increase from 2025. With a strong emphasis on research and innovation, Belgium is poised to become a key player in the global pharmaceutical industry, driving advancements in preventative healthcare and addressing the evolving challenges of infectious diseases.
Related Analysis: View Previous Industry Report
